Pharvaris reports positive topline CHAPTER-3 data for deucrictibant XR
Pharvaris says its CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of hereditary angioedema (HAE) attacks produced positive topline data, per the company announcement.